Oxbryta 500 mg film-coated tablets clinical trials

HEMolyse and Organ damage imPROvement in sickle cell disease by VoxElotor. An open-label one stage phase II design.HEMOPROVE

This study, called HEMOPROVE, is looking at a new medicine called Oxbryta for adults with sickle cell disease. Researchers want to see if this medicine can help reduce damage to red blood cells and improve how organs work, specifically by lowering a harmful type of haemoglobin in the blood.